RCR position statement on the revision of marketing authorisations for gadolinium based contrast agents

Wednesday 13 December 2017

From 1 February 2018, there will be changes to the licensing of gadolinium based intravenous contrast agents. The changes have been summarised in the RCR's position statement. This announcement from the Medicines and Healthcare products Regulations Agency has been accompanied by a message on the Central Alerting System.

Update - 29 March 2018

Following issues at the Bayer factory, they have published a letter to provide an update on the supply of Gadovist (gadobutrol) and Primovist (gadoxetate disodium)